PNPLA3 and liver disorder: Finally, our patients showed no statistically different SNPs prevalence among the liver disease severity groups, except for PNPLA3 dominant model that was more represented (as expected) in MASLD overall compared to controls, and in patients with higher risk of fibrosis (Group B) compared to those with lower risk (group A).